Skip to main content
. 2022 May 26;29(1):1663–1674. doi: 10.1080/10717544.2022.2079770

Figure 7.

Figure 7.

(A) MTT assay. (B) Morphological examination of cell line after treatment with 100 µg/mL of (1) LEF suspension, (2) LEF cubosomes (F4) and (3) Positive control (Doxorubicin). (4) MDA-MB-231 cells before treatment. (C) Percentage Cell viability of: LEF suspension, LEF cubosomes (F4) and positive control (doxorubicin).